Chugai Pharmaceutical Co., Ltd. · TSE:4519
Chugai Pharmaceutical — Q3 2013 Earnings Presentation
19 slides from Chugai Pharmaceutical's earnings presentation, Oct 25, 2013
Slide 1: FY2013 3Q Consolidated Financial Overview (IFRS based)
FY2013 3Q Consolidated C lid t d Financial Fi i l Overview O i (IFRS based) CHUGAI PHARMACEUTICAL CO., LTD. E Executive ti Vice Vi P President id t CFO Yoshio Itaya October 25, 2013
Slide 2: Forward-Looking Statements
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 3Q Consolidated Financial Overview F Forward-Looking d L ki St Statements t t This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co.
Slide 3: Summary
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 3Q Consolidated Financial Overview Summary Revenues: 306.5 billion JPY (+11.2% YoY) • Domestic sales excl. TAM (+2.0%) : continued strong growth in oncology and new products outweighed the impact from t
Slide 4: IFRS and Core Results Jan – Sep
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 3Q Consolidated Financial Overview IFRS and Core Results Jan – Sep Non-Core items IFRS results Non-core items Core results 1. Intangible/Business 2013 Intangible assets 2013 Billi Billions off JPY O Other
Slide 5: Financial Overview Jan – Sep: Year on Year (Core)
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 3Q Consolidated Financial Overview Year on Year (Core) Financial Overview Jan – Sep 2012 2013 ((Billion JPY)) p Jan - Sep Jan - Sep p Growth (Billion JPY) vs. Rev*. vs. Rev*. Royalties and other operating
Slide 6: Sales (excl. Tamiflu) Jan – Sep
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 3Q Consolidated Financial Overview Year on Year Sales (excl (excl. Tamiflu) Jan – Sep (Billion JPY) Sales excl. Tamiflu 279.7 (+19.3, +7.4%) 260.4 Overseas E Epogin i Actemra A t 45.3 -3.3 (7.8) (overseas
Slide 7: Tamiflu Sales Performance
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 3Q Consolidated Financial Overview Tamiflu Sales Performance Fiscal Term Sales (Billion JPY) FY2009 12 FY2009.12 FY2010 12 FY2010.12 FY2011 12 FY2011.12 FY2012 12 FY2012.12 FY2013 12 FY2013.12 Cases per S
Slide 8: Operating Profit Jan – Sep: Year on Year (Core)
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 3Q Consolidated Financial Overview Year on Year (Core) Operating Profit Jan – Sep 2012 2013 (Billion JPY) ((Billion JPY)) Growth Jan - Sep Jan - Sep Revenues 275.6 306.5 +30.9 Royalties and other Cost of
Slide 9: Financial Overview Jul - Sep: Year on Year (Core)
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 3Q Consolidated Financial Overview Year on Year (Core) Financial Overview Jul - Sep 2012 2013 (Billion JPY) (Billion JPY) Jul - Sep Jul - Sep Growth vs. Rev*. vs. Rev*. Royalties and other operating Reven
Slide 10: Financial Overview Jan – Sep vs. Forecast (Core)
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 3Q Consolidated Financial Overview vs. Forecast (Core) Financial Overview Jan – Sep Act al Actual Forecast on Jan 30 2012 (Billion JPY) 2013 2013 Progress Progress* Jan - Sep Jan - Dec Revenues 306 5 306.
Slide 11: Domestic Sales (excl. Tamiflu) Jan – Sep vs. Forecast
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 3Q Consolidated Financial Overview vs. Forecast Domestic Sales (excl. (excl Tamiflu) Jan – Sep Actual Forecast on 30 Jan 2012 (Billion JPY) 2013 2013 Progress Progress* Jan - Sep Jan - Dec Domestic sales
Slide 12: Impact from Foreign Exchange vs. Forecast (Core)
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2013 3Q Consolidated Financial Overview vs. Forecast (Core) Impact from Foreign Exchange FX rate to the JPY 1CHF 1EUR Assumption Jan – Dec 95.00 115.00 (as of Jan. 30) Actual Jan –Sep avg. 103.34 127.21 FX imp
Slide 13: Overview of Development Pipeline
Aiming to become “Top Pharmaceutical Company” Overview of Development Pipeline CHUGAI PHARMACEUTICAL CO., LTD. Senior Vice President Head of Project & Lifecycle Management Unit Yutaka Tanaka October 25, 2013
Slide 14: Oncology Field Projects under Development
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline Oncology Field Projects under Development (as of 25 October, 2013) Phase I Phase II Phase III Filed CIF/RG7167 (Japan/overseas) RG3502 RG1273/Perjeta RG435/Avastin - solid tumors
Slide 15: Primary Field Projects under Development
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline Primary Field Projects under Development (as of 25 October, 2013) Phase I Phase II Phase III Filed Bone RG484/Bonviva (oral) - osteoporosis & NRD101/Suvenyl Joint - enthesopathy
Slide 16: Development Status - Oncology Field
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline D Development l t St Status t - Oncology O l Fi ld Field In- In RG7446 / MPDL3280A (anti-PD-L1 MAb) : licensed Expected Indication: Solid tumors Started P1 in September 2013 In-
Slide 17: Development Status - Primary Field
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline D Development l t St Status t - Primary Pi Fi Field ld In- In Lebrikizumab / RG3637 : licensed Expected Indication: Asthma Started Global P3 in July 2013 In- Cellcept® Powder for
Slide 18: Development Status - Primary Field
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline D Development l t St Status t - Primary Pi Fi Field ld In- In ACE910 : house Expected Indication: Hemophilia A Started P1/2 in August 2013 In- MRA / Actemra® : house Subcutaneous
Slide 19: Contacts: Corporate Communications Dept.
Contacts: Corporate Communications Dept. Media Relations Group Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607 e-mail: pr@chugai-pharm.co.jp K ki H Koki Harada, d Koichi K i hi K Kawahara, h Hi hi A Hiroshi Araki, ki Sachiyo S hi Yoshimura Y hi Investor Relations Group p Tel: +81 (0)3-3273-0554 Fax:
Chugai Pharmaceutical — Q3 2013 Earnings Presentation on 6ix